These results were consistent with functions of Wnt5a reported in other human cancer types, including nasopharyngeal carcinoma (NPC) [21] and pancreatic cancer [30], which suggested that targeting Wnt/PKC signaling could resensitize cisplatin-resistant lung cancer cells to chemotherapy regimens in clinical settings. This evidence concerns the gene WNT5A and pancreatic neoplasm.